Prime Medicine Launches With $315m To Fund New Approach To Gene Editing
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
You may also be interested in...
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.